New Findings in Pulmonary Fibrosis and Post-COVID Lung Disease
Pulmonary fibrosis after COVID-19 is leaving thousands of patients struggling to breathe every day. Many are desperately searching for treatments that can actually slow or stop lung scarring.
Pirfenidone, one of the most widely used antifibrotic drugs, has been in the spotlight again with new 2025–2026 research. In this article, we break down the latest findings, how it compares with Nintedanib, and what it really means for patients.
Recent Research Findings
Recent studies published in 2025–2026 show that Pirfenidone helps slow the decline in lung function in patients with pulmonary fibrosis and other progressive fibrotic lung diseases. Researchers reported improvements in Forced Vital Capacity (FVC), which is an important indicator of lung function.
In post-COVID pulmonary fibrosis, clinical trials showed mixed but promising results. Some patients showed improvement in lung imaging and breathing capacity, while other studies found no significant difference compared to placebo. Researchers believe the drug may work better when treatment is started early in the disease.
Comparison with Other Antifibrotic Drugs
Recent comparative studies show that Pirfenidone and
Nintedanib
have similar effectiveness in slowing disease progression. Neither drug has been proven clearly superior, and treatment choice usually depends on patient tolerance, side effects, and medical condition.
New Developments in Treatment
Researchers are also developing new antifibrotic drugs such as
Nerandomilast,
which has shown promising results in progressive pulmonary fibrosis. This indicates that pulmonary fibrosis treatment options may expand in the coming years.
Conclusion
Recent research from 2025–2026 suggests that Pirfenidone remains an important antifibrotic medication for pulmonary fibrosis and post-COVID lung fibrosis. Studies show that the drug can slow lung function decline and fibrosis progression in many patients, although results are not always consistent. With ongoing clinical trials and new drug developments, treatment options for pulmonary fibrosis are expected to improve in the future.
Sources
- U.S. National Library of Medicine (PMC) – Pirfenidone in Post-COVID Pulmonary Fibrosis Review (2025)
- Clinical studies on Progressive Pulmonary Fibrosis (2025–2026)
- Comparative studies of Pirfenidone vs Nintedanib
- Recent antifibrotic drug research and approvals (2025)